AOD-9604 Pipeline, FDA Status, and What the Label Actually Says

Import from '@/components'

What Is AOD-9604 and Why Does Its Regulatory Status Matter to You?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to positions 176 through 191 of the human growth hormone (hGH) sequence. Researchers at Monash University originally isolated this fragment because it appeared to retain hGH's fat-metabolizing activity without the insulin-desensitizing effects linked to full-length hGH. That distinction drove commercial interest. The regulatory story, though, is far simpler: no country has ever granted this peptide a marketing authorization for human use.

For women, that gap matters practically. You may be offered AOD-9604 at a med-spa or compounding pharmacy for weight management, body recomposition, or metabolic support during perimenopause or in the context of PCOS. Before you accept that offer, you deserve a clear account of what regulators have and have not decided, what the clinical trial record actually contains, and where genuine scientific uncertainty begins.

The Monash University Origins

The peptide was synthesized by Professor Frank Ng's laboratory and licensed to Metabolic Pharmaceuticals Pty Ltd in the early 2000s. Early rodent work, including the frequently cited Heffernan et al. 2001 study in Endocrinology, showed that daily subcutaneous AOD-9604 reduced adipose tissue in obese mice and that the effect appeared dose-dependent without meaningful changes in IGF-1 or blood glucose. That mechanistic signal was real. What the company could never replicate was the same clear signal in humans at a scale sufficient for regulatory approval.

Why the Human Program Stalled

Metabolic Pharmaceuticals ran a series of phase II trials in Australia through the early 2000s, culminating in a phase IIb study of oral AOD-9604 formulation. Results across those trials showed weight loss that was not statistically superior to placebo at the doses tested. The company did not file a new drug application with the FDA. The program was discontinued approximately 2007. No phase III trial has ever been completed, and no NDA or BLA number exists in Drugs@FDA for AOD-9604.

The FDA Record: What Approval Actually Means (and Does Not Mean)

The FDA has not approved AOD-9604. Period. There is no NDA, no BLA, and no 505(b)(2) application listed on Drugs@FDA for this peptide. Because no approval exists, there is no official prescribing label, no FDA-mandated boxed warning, no REMS program, and no post-market surveillance requirement from a manufacturer.

503A Compounding: The Legal Gray Zone

The reason AOD-9604 is still accessible in the United States is 503A of the Federal Food, Drug, and Cosmetic Act, which permits state-licensed compounding pharmacies to prepare drug preparations for individual patients on the basis of a valid prescription from a licensed practitioner. Under 21 U.S.C. § 353a, a compounding pharmacy is not required to demonstrate efficacy or submit to the same manufacturing standards as a commercial drug manufacturer.

This creates the situation you see today: AOD-9604 is legally compounded and shipped, but the potency, sterility, and purity of each batch depend entirely on that individual pharmacy's quality-control practices. The FDA's 503A framework does not require pharmacies to conduct stability testing or to validate that the peptide in the vial matches the dose on the label.

FDA Warning Letters and Peptide Crackdowns

The FDA has, on multiple occasions, taken enforcement action against compounding pharmacies dispensing unapproved peptides. The FDA's 2022 and 2023 guidance documents on bulk drug substances placed several peptides under heightened scrutiny. AOD-9604 does not appear on the current 503A Bulks List as a substance that has been evaluated and nominated for inclusion. That omission means it occupies a legally uncertain position: not explicitly prohibited in all jurisdictions, but also not affirmatively permitted by a formal FDA evaluation.

What "No Label" Means for You

Without an approved label, there is no standardized dosing instruction, no contraindication list, no drug-interaction table, and no pregnancy category assigned by a regulatory body. Any dosing information you receive from a compounding pharmacy or telehealth prescriber is derived from the early Metabolic Pharmaceuticals trial protocols or from practitioner experience, not from an FDA-reviewed document.

The Pipeline: Is an Approved AOD-9604 Product Coming?

No active IND or phase III trial for AOD-9604 appears in ClinicalTrials.gov as of mid-2025. The original developer is no longer advancing the compound. Academic interest continues, particularly in Australia and South Korea, focused primarily on cartilage and osteoarthritis applications rather than weight loss.

Osteoarthritis Research: The More Active Frontier

The most scientifically plausible next-generation application for AOD-9604 may not be weight management at all. Several small studies have explored intra-articular injection for knee osteoarthritis, a condition highly relevant to women: women develop knee osteoarthritis at higher rates than men after age 50, and estrogen withdrawal at menopause accelerates cartilage loss. Research published in Cartilage and related journals suggests AOD-9604 may promote proteoglycan synthesis and chondrocyte activity, but sample sizes remain very small, and no regulatory submission has followed.

Combination Peptide Formulations

Compounding pharmacies increasingly offer AOD-9604 in fixed combinations with other peptides, most commonly AOD-9604 plus ipamorelin, or AOD-9604 plus CJC-1295. These combinations have no regulatory basis whatsoever. No trial has tested them for safety or efficacy in women, and the pharmacokinetic interaction between peptides in a multi-compound vial is unstudied. The FDA has specifically noted that combining unapproved drug substances in a compounded preparation does not confer safety on the resulting product.

EMA and International Status

The European Medicines Agency has no EPAR (European Public Assessment Report) for AOD-9604. The peptide does not hold a marketing authorization in any EU member state. In Australia, the Therapeutic Goods Administration (TGA) lists AOD-9604 as a Schedule 4 substance, meaning it requires a prescription, but it is not TGA-registered as a therapeutic good for any indication.

Sex-Specific Physiology: How Women's Biology Changes the Picture

The entire AOD-9604 clinical trial record is sparse, but the sex-stratified data is nearly nonexistent. Every woman considering this peptide should understand that the available evidence was generated predominantly in mixed-sex or male-predominant cohorts, or in rodent models. Here is what that means across life stages.

Reproductive Years and the Menstrual Cycle

Growth hormone secretion is not static across the menstrual cycle. Estrogen upregulates hepatic GH receptors and modulates pulsatile GH secretion, with GH pulse amplitude highest in the follicular phase. Whether the fragment AOD-9604 behaves differently across cycle phases is entirely unknown. No published study has measured AOD-9604 pharmacokinetics at different cycle points in women. Women in their reproductive years who are prescribed this peptide are receiving a dose calibrated for no one in particular.

PCOS and Metabolic Context

Women with PCOS frequently carry a metabolic profile that includes visceral adiposity, insulin resistance, and elevated androgen levels, a combination that also alters GH axis function. Studies show that women with PCOS have blunted GH pulsatility and altered IGF-1 sensitivity compared with age-matched controls. The theoretical appeal of a lipolytic peptide that bypasses IGF-1 is therefore real. The evidence that AOD-9604 actually delivers fat loss in this population does not exist in peer-reviewed form. Prescribing it for PCOS-related weight management is extrapolation from rodent lipolysis data.

Perimenopause and Menopause

Estrogen decline in perimenopause shifts fat distribution toward the abdomen and reduces GH pulse frequency. This is a stage where women are most likely to encounter AOD-9604 marketing. The SWAN study documented that the menopausal transition independently predicts a gain of approximately 2 kg of fat mass regardless of changes in total caloric intake, a shift driven partly by GH axis changes. The logic that augmenting lipolytic signaling could counteract this is mechanistically plausible, but it remains tested only in theory, not in perimenopausal women assigned AOD-9604 in a controlled trial.

Bone Health Consideration

One signal worth monitoring is bone turnover. Full-length GH is anabolic for bone. AOD-9604 does not appear to activate the GH receptor in the same way and has not been shown to increase IGF-1, which is the primary mediator of GH's bone-building effect. For postmenopausal women already at risk of osteoporosis, choosing a peptide with no demonstrated bone benefit over agents with proven data (raloxifene, bisphosphonates, denosumab, romosozumab) is a trade-off that deserves explicit discussion with your prescriber.

Pregnancy, Lactation, and Contraception

AOD-9604 should not be used during pregnancy or while breastfeeding. This is not a cautious hedge. It is the appropriate position given a total absence of human gestational safety data.

Pregnancy

No animal reproductive toxicology studies for AOD-9604 have been published in peer-reviewed journals. No FDA pregnancy category was ever assigned because the drug was never approved. No registry data exists. Under the FDA's current Pregnancy and Lactation Labeling Rule (PLLR), an approved drug must disclose pregnancy risk information in a standardized format. AOD-9604 has none of this, because it is not approved.

GH fragments can affect fetal growth signaling. The placenta expresses GH receptors and produces placental GH variants. Introducing an exogenous fragment with beta-3 adrenergic and possibly GH-receptor partial agonist activity during organogenesis or fetal growth is a biologically plausible risk that has simply never been studied.

If you are trying to conceive, currently pregnant, or think you might be pregnant: do not use AOD-9604.

Contraception Requirement

Because the safety profile in early pregnancy is genuinely unknown and potentially concerning given GH axis involvement in implantation and early fetal development, women of reproductive age using AOD-9604 should use reliable contraception. Discuss this explicitly with your prescriber before starting.

Lactation

AOD-9604 is a peptide with a molecular weight of approximately 1,815 daltons. Peptides of this size can transfer into breast milk, though GI degradation in the infant may limit systemic absorption. No lactation transfer data exists. Given the complete absence of infant safety data, AOD-9604 should be discontinued before breastfeeding begins, and the decision to restart postpartum should be deferred until breastfeeding has ended.

AOD-9604 Safety: What the Available Evidence Does and Does Not Tell Us

The safety record for AOD-9604 is thin but not empty. Across the Metabolic Pharmaceuticals trial program, the oral formulation was generally described as well tolerated, with adverse events similar to placebo. The subcutaneous formulations now in compounding use carry a different risk profile, because injection bypasses GI degradation and delivers the peptide directly into systemic circulation.

Known and Theoretical Risks

• Injection site reactions. Subcutaneous peptide injections can produce redness, induration, and nodule formation. This is consistent across all compounded peptide products and is not unique to AOD-9604.
• Hypoglycemia. The Heffernan et al. 2001 paper specifically showed that AOD-9604 did not alter glucose or insulin in the rodent model, which was presented as a safety advantage over full hGH. Human glucose effects remain underpowered in trial data.
• Unknown long-term effects. No study has followed humans using AOD-9604 beyond 12 weeks. The peptide is being used indefinitely by some patients. Long-term receptor desensitization, immunogenicity, and organ-level effects are entirely unstudied.
• Compounding contamination risk. The FDA has documented contamination events in compounded injectable products. Every injectable compounded peptide carries this risk.

What the FDA Sentinel System Covers (and Doesn't)

The FDA Sentinel System monitors post-market safety signals in approved drug products using insurance claims and electronic health records. AOD-9604 generates no Sentinel data because it is not an approved product. Adverse event reports may be submitted to FDA MedWatch, but compounded peptide use is chronically under-reported and the cases that are submitted are difficult to attribute because patients often use multiple peptides simultaneously.

The Evidence Gap Is Not Neutral

Women have been historically under-represented in metabolic drug trials. In the AOD-9604 case, the problem is more fundamental: there is no meaningful trial database at all. Every safety claim made about this peptide in a clinical or commercial setting is extrapolated from early-phase rodent data, small oral-formulation trials, and post-market anecdote. Acknowledging that gap is not a reason to panic, but it is a reason to apply a high bar of justification before use, particularly at sensitive life stages.

Who This May Be Right For (and Who Should Avoid It)

No woman is a perfect candidate for an unapproved, unstandardized compounded peptide with no phase III data. The practical reality is that some women will consider AOD-9604 after exhausting other options, and a realistic framing is more useful than a blanket dismissal.

Situations Where the Risk-Benefit Calculation Is Least Unfavorable

• Postmenopausal women not on hormone therapy, not planning pregnancy, not breastfeeding, with well-documented metabolic obesity who have not responded to approved agents and who fully understand they are participating in an evidence-free intervention.
• Women with PCOS and visceral adiposity who cannot tolerate GLP-1 receptor agonists and who have ruled out FDA-approved weight-loss pharmacotherapy, with eyes open to the lack of PCOS-specific data.

Even in these situations, the absence of a standardized product means quality of the compounded peptide is a real variable, and "trying it" cannot be monitored against a known dose-response curve.

Situations Where AOD-9604 Should Be Avoided

• Pregnancy (any trimester) or preconception without reliable contraception.
• Breastfeeding.
• Postpartum (first 12 months, during which hormonal and metabolic axes are still restabilizing).
• Adolescents and young adults with open growth plates, given the theoretical GH-axis interaction.
• Women with active cancer or a history of hormone-sensitive malignancy, as GH-axis peptides in this setting lack safety data.
• Women already achieving satisfactory results with approved pharmacotherapy (semaglutide, tirzepatide, naltrexone-bupropion, phentermine-topiramate) should not add AOD-9604 without a clear clinical rationale.

Questions to Ask Your Prescriber Before Starting

The questions below are not comprehensive, but they represent the minimum a thoughtful prescriber should be able to answer before you proceed.

1. Which compounding pharmacy will prepare this, and do they hold PCAB accreditation or equivalent third-party quality certification?
2. What dose and frequency are you prescribing, and what is that based on?
3. How will we monitor whether this is working or causing harm, and over what time frame?
4. Are you aware that no FDA-approved label exists and that I have no regulatory protection if I experience an adverse event?
5. If I decide to try to conceive in the next six months, when should I stop?

A prescriber who cannot answer these questions clearly is not the right prescriber for an off-label, unapproved compounded peptide.